| The effectiveness of direct to healthcare professional communication–a systematic review of communication factor studies M Møllebæk, S Kaae, ML De Bruin, T Callréus, S Jossan, CE Hallgreen Research in Social and Administrative Pharmacy 15 (5), 475-482, 2019 | 18 | 2019 |
| Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings AL Bhasale, A Sarpatwari, W Lipworth, M Møllebæk, EJ McEwin, ... British Journal of Clinical Pharmacology 88 (2), 713-722, 2022 | 9 | 2022 |
| Preparation of direct healthcare professional communication: an exploratory study on the experiences and perceptions of European pharmaceutical companies and the EMA A Boskovic, M Møllebæk, S Kaae Therapeutic innovation & regulatory science 54, 631-639, 2020 | 7 | 2020 |
| Why do general practitioners disregard direct to healthcare professional communication? A user‐oriented evaluation to improve drug safety communication M Møllebæk, S Kaae Basic & Clinical Pharmacology & Toxicology 128 (3), 463-471, 2021 | 6 | 2021 |
| Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab A Fabbri, M O'Keeffe, R Moynihan, M Møllebæk, A Mohammad, A Bhasale, ... British Journal of Clinical Pharmacology 86 (7), 1416-1429, 2020 | 5 | 2020 |
| Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts MA Hogervorst, M Møllebæk, RA Vreman, TA Lu, J Wang, ML De Bruin, ... BMJ open 13 (8), e072309, 2023 | 3 | 2023 |
| Are Drug Safety Advisories Compatible with Physicians’ Information Behaviour? Semi-Structured Interviews with General Practitioners about Direct to Healthcare Professional … M Møllebæk, S Kaae European Journal of Health Communication 3 (3), 1-17, 2022 | 2 | 2022 |
| Challenges in qualitative social pharmacy research: Reflections based on a conference workshop SK Sporrong, S Kaae, LS Nørgaard, M Møllebæk, M Waaseth, LC Arevalo, ... Research in Social and Administrative Pharmacy 18 (1), 2254-2258, 2022 | 2 | 2022 |
| Regulating patient access to therapeutics in Denmark: a rhetorical analysis of welfare imaginaries in public controversy M Møllebæk Journal of Law and the Biosciences 8 (2), lsaa047, 2021 | 2 | 2021 |
| Rhetoric and science and technology studies M Møllebæk Communicating about risks and safe use of medicines: real life and applied …, 2020 | 2 | 2020 |
| Mod en hverdagsetik for lægemiddelbrug: Om mennesker, medicin og multiplicitet SR Lau, M Møllebæk Tidsskrift for Forskning i Sygdom og Samfund 19 (37), 19-41, 2022 | 1 | 2022 |
| Pharmaceuticalization M Møllebæk Palgrave Encyclopedia of the Health Humanities, 1-5, 2021 | 1 | 2021 |
| Paper Tigers in the Clinic? Rhetorical Argument Fields in Health Policy Implementation M Møllebæk Rhetorical Argumentation: The Copenhagen School, 408, 2023 | | 2023 |
| Challenges in qualitative social pharmacy research: Reflections based on a conference workshop S Kalvemark Sporrong, S Kaae, LS Norgaard, M Mollebaek, M Waaseth, ... | | 2022 |
| Methodological and disciplinary competence and insecurity in qualitative research SK Sporrong, S Kaae, LS Nørgaard, M Møllebæk, M Waaseth, LC Arevalo, ... Contemporary Research Methods in Pharmacy and Health Services, 567-573, 2022 | | 2022 |
| PROGRAMME DESCRIPTION: Using real-world cases, innovation and rhetorical tools to teach social pharmacy LS Nørgaard, M Møllebæk, PL Halstrøm, NLF Riis, VB Christensen, ... Pharmacy Education 21, 555-568, 2021 | | 2021 |
| Formative Evaluation of Direct to Healthcare Professional Communication M Møllebæk DEPARTMENT OF PHARMACY PhD Thesis Mathias Møllebæk Formative Evaluation of …, 2020 | | 2020 |
| POST-MARKETING RISK COMMUNICATION: HOW DO DANISH GPS READ LETTERS FROM REGULATORS AND INDUSTRY ABOUT EMERGENT RISKS? M Møllebæk, S Kaae, L Villadsen Research in Social and Administrative Pharmacy 15 (12), 2019 | | 2019 |
